Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
38 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Abivax SA’s names, not what it holds today.
Patents granted
38
38 utility, 1976 to Dec 31, 2025
Granted in 2025
4
Against 2 in 2024 and 4 in 2023
Applications published
47
6 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Organic fine chemistry8
Pharmaceuticals8
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
ABIVAX its own name
FR, as the owner printed on each patent
36 publishedABIVAX its own name
named as the applicant on its applications, in FR
11 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Nov 25, 2025 | 12,479,802 | Phenyl-n-quinoline derivatives for treating a RNA virus infection | Organic fine chemistry | ABIVAX |
| Sep 23, 2025 | 12,421,206 | Aryl-n-aryl derivatives for treating a RNA virus infection | Organic fine chemistry | ABIVAX |
| Mar 11, 2025 | 12,247,018 | Aryl-n-aryl derivatives for treating a RNA virus infection | Organic fine chemistry | ABIVAX |
| Jan 21, 2025 | 12,202,804 | In vitro or ex vivo methods for screening a quinoline derivative | Pharmaceuticals | ABIVAX |
| Sep 10, 2024 | 12,084,422 | Phenyl-n-quinoline derivatives for treating a RNA virus infection | Organic fine chemistry | ABIVAX |
| May 28, 2024 | 11,992,499 | Quinoline derivatives for use in the treatment of inflammation diseases | Pharmaceuticals | ABIVAX |
| Nov 28, 2023 | 11,826,372 | Combinations including ABX196 for the treatment of cancer | Pharmaceuticals | ABIVAX |
| Aug 29, 2023 | 11,739,073 | Aryl-n-aryl derivatives for treating a RNA virus infection | Organic fine chemistry | ABIVAX |
| May 16, 2023 | 11,649,211 | Use of quinoline derivatives for the treatment of inflammatory diseases | Pharmaceuticals | ABIVAX |
| May 16, 2023 | 11,649,210 | Use of quinoline derivatives for the treatment of inflammatory diseases | Pharmaceuticals | ABIVAX |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Sep 4, 2025 | 2025/0275994 | Quinoline Derivatives For Use In The Treatment Of Inflammation Diseases | Pharmaceuticals | ABIVAX |
| May 29, 2025 | 2025/0170119 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | Pharmaceuticals | ABIVAX |
| May 8, 2025 | 2025/0145651 | METHOD OF PREPARATION OF 1-(N-(QUINOLIN-2-YL)-(PHENYLAMINO)-1-DEOXY-BETA-D-GLUCOPYRANURONIC ACID DERIVATIVES | Organic fine chemistry | ABIVAX |
| Mar 27, 2025 | 2025/0100971 | IN VITRO OR EX VIVO METHODS FOR SCREENING A QUINOLINE DERIVATIVE | Pharmaceuticals | ABIVAX |
| Mar 27, 2025 | 2025/0099454 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A JAK INHIBITOR | Pharmaceuticals | ABIVAX |
| Jan 30, 2025 | 2025/0032474 | COMBINATION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE AND ITS DERIVATIVES WITH A S1P RECEPTOR MODULATOR | Pharmaceuticals | ABIVAX |
| Oct 17, 2024 | 2024/0343716 | COMPOUNDS FOR PREVENTING, INHIBITING, OR TREATING CANCER, AIDS AND/OR PREMATURE AGING | Organic fine chemistry | ABIVAX |
| Sep 19, 2024 | 2024/0308964 | PHENYL-N-QUINOLINE DERIVATIVES FOR TREATING A RNA VIRUS INFECTION | Organic fine chemistry | ABIVAX · patent 12,479,802 granted from it |
| Jun 6, 2024 | 2024/0182422 | PREPARATION METHOD OF QUINOLINE DERIVATIVE COMPOUNDS | Organic fine chemistry | ABIVAX |
| Jul 13, 2023 | 2023/0218605 | AMORPHOUS SOLID DISPERSION OF 8-CHLORO-N-(4-(TRIFLUOROMETHOXY)PHENYL)QUINOLIN-2-AMINE | Pharmaceuticals | ABIVAX |
What it applied for, 2024 to 2025: Pharmaceuticals 5 · Organic fine chemistry 4.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.